 "Novartis")
India’s Rs 20,000-crore cardiac drug market is in for a shake-up as generic launches of Novartis’ heart-failure drug Vymada begin. Mumbai-based Glenmark Pharmaceuticals on Monday announced the launch of their own brand of Sacubitril-valsartan tablets Sacu V, priced between Rs 19-35 per tablet.
Sheetal Sapale, president (marketing), AIOCD-AWACS said that at least 40 more brands are expected to be launched in this category, leading to a price erosion of at least 50 per cent.
Earlier in December, JB Pharma, which had acquired the Azmarda brand from Novartis AG, Switzerland for the India region for a consideration of Rs 246 crores in April 2022, had slashed its prices by half to Rs 39.6 per tablet. Only four companies were marketing Novartis’
